FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129336404> ?p ?o ?g. }

• W2129336404 endingPage "e37" @default.
• W2129336404 startingPage "e37" @default.
• W2129336404 abstract "We describe 2 cases of angioblastoma, a rare, destructive pediatric tumor, treated with interferon alfa 2b (IFNalpha2b). The first patient is a 10-month-old male who presented with an ulcerated palatal neoplasm that could not be completely resected. The second is a male neonate with a congenital tumor of the right hand that invaded the hypothenar eminence, destroying the fourth and fifth metacarpals. Biopsy in both patients was interpreted as giant cell angioblastoma. Angioblastoma is rare; there is only 1 reported case that necessitated amputation of an upper extremity, also initially recommended for our patient. Because there is little experience with chemotherapy, permission was granted to employ an antiangiogenic regimen of IFNalpha2b. The angiogenic protein, basic fibroblast growth factor (bFGF), was abnormally elevated in both patients. Both patients received IFNalpha2b. In the first child, it was used after incomplete resection, because biopsy-proven tumor was present at the margin and in the nasopharynx. Biopsies 15 months after initiation of IFN2alphab were negative for tumor. Therapy was stopped after 3 years. Eighteen months later, the patient remains disease-free. In the second child, IFNalpha2b was started after debridement of the ulcerated tumor. Over 11 months, the tumor completely regressed and there was bony regeneration of the metacarpals. The fifth digit was amputated because of damage to the metacarpophalangeal joint by the tumor. IFNalpha2b therapy was discontinued after 1 year of treatment, and the child remains disease-free 2 years and 8 months later. In conclusion, this report demonstrates that: 1) a bFGF-overexpressing low-grade tumor can respond to IFNalpha2b in a manner similar to life-threatening infantile hemangiomas, 2) urinary bFGF levels can help guide IFNalpha dosage in such patients, and 3) although bFGF-mediated tumor angiogenesis is inhibited by IFNalpha, physiologic angiogenesis seems to be unaffected." @default.
• W2129336404 created "2016-06-24" @default.
• W2129336404 creator A5003605734 @default.
• W2129336404 creator A5011956202 @default.
• W2129336404 creator A5026608308 @default.
• W2129336404 creator A5053339332 @default.
• W2129336404 creator A5053768944 @default.
• W2129336404 creator A5063237385 @default.
• W2129336404 creator A5083281030 @default.
• W2129336404 creator A5088978035 @default.
• W2129336404 date "2002-02-01" @default.
• W2129336404 modified "2023-09-27" @default.
• W2129336404 title "Successful Antiangiogenic Therapy of Giant Cell Angioblastoma With Interferon Alfa 2b: Report of 2 Cases" @default.
• W2129336404 cites W1539254583 @default.
• W2129336404 cites W1976454127 @default.
• W2129336404 cites W1978139448 @default.
• W2129336404 cites W1980414070 @default.
• W2129336404 cites W1981486175 @default.
• W2129336404 cites W1984726928 @default.
• W2129336404 cites W1984753966 @default.
• W2129336404 cites W1992590508 @default.
• W2129336404 cites W1995028613 @default.
• W2129336404 cites W1996013492 @default.
• W2129336404 cites W2000000541 @default.
• W2129336404 cites W2006628947 @default.
• W2129336404 cites W2006904593 @default.
• W2129336404 cites W2008103949 @default.
• W2129336404 cites W2010476650 @default.
• W2129336404 cites W2011064880 @default.
• W2129336404 cites W2028332492 @default.
• W2129336404 cites W2034930381 @default.
• W2129336404 cites W2049705652 @default.
• W2129336404 cites W2056789644 @default.
• W2129336404 cites W2063218207 @default.
• W2129336404 cites W2064624801 @default.
• W2129336404 cites W2068053554 @default.
• W2129336404 cites W2079769967 @default.
• W2129336404 cites W2081727254 @default.
• W2129336404 cites W2093915058 @default.
• W2129336404 cites W2116926169 @default.
• W2129336404 cites W2118449798 @default.
• W2129336404 cites W2160606227 @default.
• W2129336404 cites W2320276399 @default.
• W2129336404 cites W2330494542 @default.
• W2129336404 cites W2340893063 @default.
• W2129336404 doi "https://doi.org/10.1542/peds.109.2.e37" @default.
• W2129336404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11826247" @default.
• W2129336404 hasPublicationYear "2002" @default.
• W2129336404 type Work @default.
• W2129336404 sameAs 2129336404 @default.
• W2129336404 citedByCount "75" @default.
• W2129336404 countsByYear W21293364042012 @default.
• W2129336404 countsByYear W21293364042013 @default.
• W2129336404 countsByYear W21293364042014 @default.
• W2129336404 countsByYear W21293364042015 @default.
• W2129336404 countsByYear W21293364042016 @default.
• W2129336404 countsByYear W21293364042019 @default.
• W2129336404 countsByYear W21293364042020 @default.
• W2129336404 countsByYear W21293364042021 @default.
• W2129336404 countsByYear W21293364042023 @default.
• W2129336404 crossrefType "journal-article" @default.
• W2129336404 hasAuthorship W2129336404A5003605734 @default.
• W2129336404 hasAuthorship W2129336404A5011956202 @default.
• W2129336404 hasAuthorship W2129336404A5026608308 @default.
• W2129336404 hasAuthorship W2129336404A5053339332 @default.
• W2129336404 hasAuthorship W2129336404A5053768944 @default.
• W2129336404 hasAuthorship W2129336404A5063237385 @default.
• W2129336404 hasAuthorship W2129336404A5083281030 @default.
• W2129336404 hasAuthorship W2129336404A5088978035 @default.
• W2129336404 hasConcept C126322002 @default.
• W2129336404 hasConcept C141071460 @default.
• W2129336404 hasConcept C142724271 @default.
• W2129336404 hasConcept C170493617 @default.
• W2129336404 hasConcept C2775934546 @default.
• W2129336404 hasConcept C2775960820 @default.
• W2129336404 hasConcept C2776204877 @default.
• W2129336404 hasConcept C2776694085 @default.
• W2129336404 hasConcept C2777587049 @default.
• W2129336404 hasConcept C2781413609 @default.
• W2129336404 hasConcept C71924100 @default.
• W2129336404 hasConceptScore W2129336404C126322002 @default.
• W2129336404 hasConceptScore W2129336404C141071460 @default.
• W2129336404 hasConceptScore W2129336404C142724271 @default.
• W2129336404 hasConceptScore W2129336404C170493617 @default.
• W2129336404 hasConceptScore W2129336404C2775934546 @default.
• W2129336404 hasConceptScore W2129336404C2775960820 @default.
• W2129336404 hasConceptScore W2129336404C2776204877 @default.
• W2129336404 hasConceptScore W2129336404C2776694085 @default.
• W2129336404 hasConceptScore W2129336404C2777587049 @default.
• W2129336404 hasConceptScore W2129336404C2781413609 @default.
• W2129336404 hasConceptScore W2129336404C71924100 @default.
• W2129336404 hasIssue "2" @default.
• W2129336404 hasLocation W21293364041 @default.
• W2129336404 hasLocation W21293364042 @default.
• W2129336404 hasOpenAccess W2129336404 @default.
• W2129336404 hasPrimaryLocation W21293364041 @default.
• W2129336404 hasRelatedWork W1516518892 @default.
• W2129336404 hasRelatedWork W1586374228 @default.

• next